Biogen Inc. ($BIIB) Stock Forecast: Up 3.1% Today

What is Biogen Inc.?

Biogen Inc. (BIIB) is a biotechnology company with a focus on developing therapies for neurological and neurodegenerative diseases. The stock experienced a notable upward trend today.

Why is Biogen Inc. going up?

BIIB stock is up 3.1% on Oct 31, 2025 14:40

• BIIB surpassed Q3 earnings and revenue expectations, leading to an initial decline in its stock price following the company's reduction of its 2025 EPS forecast.
• The approval from Health Canada for "LEQEMBI®" to treat early Alzheimer's disease likely contributed to the stock's positive movement.
• Analysts highlighting the potential of Biogen's long-term immunology pipeline, particularly after a recent licensing agreement, may have boosted investor confidence in the company.
• The stock's bullish performance can be attributed to a mix of strong financial results, favorable regulatory milestones, and promising developments in Biogen's product pipeline.

BIIB Price Chart

BIIB Technical Analysis

BIIB News

BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View

Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.

https://www.zacks.com/stock/news/2781905/biib-beats-on-q3-earnings-sales-stock-down-on-lowered-25-eps-view

Biogen Inc. ( BIIB ) Q3 Earnings and Revenues Top Estimates

Biogen (BIIB) delivered earnings and revenue surprises of +23.65% and +8.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2781046/biogen-inc-biib-q3-earnings-and-revenues-top-estimates

Health Canada Grants Authorization for "LEQEMBI®" ( lecanemab ) for the Treatment of Early Alzheimer's Disease

In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease ( early AD ) who are apolipoprotein E ε4 ( ApoE ε4* ) non-carriers or heterozygotes and who have confirmed amyloid pathology In ...

https://www.globenewswire.com/news-release/2025/10/26/3174281/0/en/Health-Canada-Grants-Authorization-for-LEQEMBI-lecanemab-for-the-Treatment-of-Early-Alzheimer-s-Disease.html

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst - Biogen ( NASDAQ:BIIB )

On Friday, Biogen Inc. ( NASDAQ:BIIB ) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48411482/biogens-immunology-pipeline-has-long-term-potential-analyst

Trending Today

Penn National Gaming Inc. ($PENN) Stock Forecast: Down 5.0% Today

Carvana Co ($CVNA) Stock Forecast: Down 5.2% Today

Astera Labs Inc ($ALAB) Stock Forecast: Down 5.2% Today

CF Industries Holdings Inc. ($CF) Stock Forecast: Down 5.2% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Up 11.3% Today

Circle Internet Group ($CRCL) Stock Forecast: Down 6.3% Today

Kornit Digital Ltd. ($KRNT) Stock Forecast: Down 5.1% Today

Western Union Company (The) ($WU) Stock Forecast: Up 5.5% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 5.8% Today

TKO Group Holdings Inc ($TKO) Stock Forecast: Down 5.4% Today

Biogen Inc. Price History

07.02.2025 - BIIB Stock was up 5.2%

• BIIB stock exhibited a bullish trend despite worries about the pricing of Alzheimer's drugs from Biogen and Eli Lilly.
• Investor optimism towards the potential market demand for Biogen's treatments persists despite pricing concerns.
• The bullish movement reflects confidence in Biogen's capacity to address pricing challenges and advance pioneering therapies in neurology.

31.09.2025 - BIIB Stock was up 3.1%

• BIIB surpassed Q3 earnings and revenue expectations, leading to an initial decline in its stock price following the company's reduction of its 2025 EPS forecast.
• The approval from Health Canada for "LEQEMBI®" to treat early Alzheimer's disease likely contributed to the stock's positive movement.
• Analysts highlighting the potential of Biogen's long-term immunology pipeline, particularly after a recent licensing agreement, may have boosted investor confidence in the company.
• The stock's bullish performance can be attributed to a mix of strong financial results, favorable regulatory milestones, and promising developments in Biogen's product pipeline.

30.09.2025 - BIIB Stock was up 2.3%

• Biogen (BIIB) reported impressive Q3 earnings and revenues, surpassing estimates by a significant margin, indicating strong financial performance.
• Health Canada granting authorization for "LEQEMBI®" for the treatment of Early Alzheimer's Disease is a significant milestone for Biogen, boosting investor confidence in the company's Alzheimer's treatment pipeline.
• The licensing agreement with Vanqua Bio to acquire exclusive rights to a preclinical oral C5aR1 antagonist strengthens Biogen's immunology portfolio, highlighting the company's commitment to innovation and expansion in the healthcare sector.
• The positive news surrounding Biogen's financials, advancements in Alzheimer's treatment, and expansion of its immunology pipeline likely contributed to the bullish movement in the stock today.

01.04.2025 - BIIB Stock was up 3.7%

• BIIB stock surged as investors were impressed by the company's strong performance in the first quarter of 2025.
• Despite Sage Therapeutics' disappointing earnings, BIIB's robust financial results and promising outlook for key metrics exceeded Wall Street estimates, driving up the stock price.
• The market reacted favorably to BIIB's Q1 outlook, indicating confidence in the company's ability to deliver solid results and maintain its position as a key player in the biotech industry.
• Overall, BIIB's bullish movement can be attributed to its strong fundamentals and positive market expectations, contrasting with the underperformance of some of its industry peers.

06.04.2025 - BIIB Stock was down 5.1%

• Following its Q1 earnings release, BIIB witnessed a significant decrease in stock value.
• BIIB outperformed earnings projections, posting an EPS of $3.02 compared to the estimated $2.52, and recorded a revenue surge to $2.43 billion, exceeding the expected $2.23 billion.
• Despite the positive earnings outcome, BIIB's stock faced a decline, potentially due to the mixed Q1 performance and the company's downward revision of its EPS guidance for the year.
• The market response to the revised guidance hints at apprehensions regarding future growth and performance, contributing to the bearish movement in BIIB's stock price today.

26.06.2024 - BIIB Stock was down 8.2%

• The rejection of Biogen and Eisai's Alzheimer's drug, lecanemab, by the European Medicines Agency, citing concerns about its efficacy in early-stage Alzheimer's, led to a notable decrease in Biogen's stock value.
• The negative feedback from the Committee for Medicinal Products for Human Use (CHMP) highlighted the regulatory challenges faced by both companies, impacting investor trust in the drug's potential success.
• This rejection emphasizes the difficulties in creating effective Alzheimer's treatments and the necessity for strong clinical evidence to support approval, resulting in a pessimistic outlook on Biogen's stock.
• As attention shifts to Biogen's upcoming second-quarter earnings call, investors are eager to learn how the company plans to address this setback and navigate the regulatory environment for its Alzheimer's therapy.

04.03.2025 - BIIB Stock was down 5.0%

• BIIB's stock likely dropped due to the positive announcement of its experimental Alzheimer's drug receiving FDA's fast track designation, potentially heightening optimism for its future success.
• Eli Lilly's Alzheimer's drug received a negative assessment from the European Medicines Agency (EMA), indirectly benefitting Biogen by reducing competition in the Alzheimer's treatment sector.
• Investor sentiment appears to favor Biogen over Eli Lilly, given the challenges the latter faces in gaining regulatory approval for its Alzheimer's drug.
• The divergent paths of the two companies in Alzheimer's drug development may have influenced market outlook towards Biogen, contributing to the downward movement in its stock value today.

13.01.2025 - BIIB Stock was up 5.3%

• Biogen reported better-than-expected earnings for its fourth quarter, with adjusted EPS beating consensus estimates.
• Despite the positive earnings report, Biogen's 2025 EPS guidance fell short of expectations, leading to some analyst downgrades.
• The market reacted positively to Biogen's cost-cutting measures and the potential of new drugs like Leqembi, which are expected to offset revenue declines from existing products.
• Overall, the bullish movement in Biogen's stock can be attributed to the company's strong financial performance in Q4, despite some concerns about future earnings guidance.

12.01.2025 - BIIB Stock was down 5.1%

• Despite surpassing earnings and revenue projections in Q4, BIIB experienced a bearish market movement, suggesting potentially elevated market anticipations.
• The projection of profits fell below expectations despite efforts such as cost reductions and the introduction of new medications like Leqembi, indicating possible investor dissatisfaction with the company's future prospects.
• An increase in optimistic positions on BIIB through options trading potentially heightened market volatility and profit-taking, contributing to the downward trend.
• The decrease in sales of multiple sclerosis treatments and Spinraza was balanced by revenues from new drugs, but this may not have met investor expectations, resulting in the bearish market movement.

12.01.2025 - BIIB Stock was down 8.1%

• Biogen exceeded expectations with cost reduction efforts and the launch of Leqembi, but a lower profit outlook caused a decline in the stock price.
• The FDA's approval of a maintenance dosing regimen for Leqembi in Alzheimer's was a positive development, while decreased sales of multiple sclerosis drugs and Spinraza likely impacted revenue.
• Investor optimism in the options market suggests confidence in the long-term potential of Biogen's new drugs, despite short-term profit concerns.
• The forthcoming Q4 earnings report will be essential in offering more insight into the company's financial performance and the effects of new drugs on revenue.

01.07.2025 - BIIB Stock was down 6.0%

• Biogen exceeded earnings and revenue projections for Q2 2025, but its stock faced a downward trend.
• Concerns arose over the drop in sales of MS medications, despite the promising growth exhibited by newer drugs like Leqembi and Skyclarys.
• Investors are exercising caution regarding the company's overall prospects, given the balance between declining sales of MS drugs and gains from newer products.
• While the initial market response to the strong earnings and raised forecasts was positive, uncertainties about Biogen's future performance in the competitive pharmaceutical industry may be dampening investor sentiment.

01.09.2025 - BIIB Stock was up 5.1%

• BIIB stock showed significant growth in trading today.
• The approval of "LEQEMBI®" for Early Alzheimer's Disease treatment in China is believed to have influenced the positive market sentiment.
• Although they received a Complete Response Letter from the FDA for a different drug application, the initiation of bullish coverage by analysts may have outweighed this development.
• Favorable analyst coverage and optimistic forecasts for Biogen likely boosted investor confidence and contributed to the stock's upward trajectory.